You are here: Industry Insights > Kadcyla

News List

Final NHS green light for Roche's Kadcyla pharmatimes
June 11, 2020
NICE has published final guidance backing NHS use of Roche's Kadcyla (trastuzumab emtansine) for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2) positive early breast cancer.
UK’s NICE recommends Roche breast cancer drug Kadcyla pharmaceutical-technology
May 12, 2020
The National Institute for Health and Care Excellence (NICE) in the UK has recommended the use of Roche’s Kadcyla (trastuzumab emtansine) to treat certain patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
FDA Approves Roche's Kadcyla for HER2-Positive Early Breast Cancer contractpharma
June 14, 2019
An adjuvant treatment for patients who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.
Roche’s Kadcyla cuts risk of breast cancer recurrence after surgery pharmatimes
December 07, 2018
Roche’s Kadcyla was significantly better than Herceptin at reducing the risk of breast cancer recurrence in certain patients with residual disease after surgery, according to new study findings presented at the San Antonio Breast Cancer Symposium.
Roche unveils data for Kadcyla move into early breast cancer fiercepharma
December 06, 2018
Roche is hoping to grow sales for new drugs as biosim competition begins to erode its top blockbusters, and now the drugmaker has unveiled new data that just might give its breast cancer drug Kadcyla a boost.
Roche aims for Kadcyla expansion with new early breast cancer data fiercepharma
December 06, 2018
Roche is hoping to grow sales for new drugs as biosim competition begins to erode its top blockbusters, and now the drugmaker has unveiled new data that just might give its breast cancer drug Kadcyla a boost.
Roche’s Kadcyla shows promise in early breast cancer pharmatimes
October 19, 2018
Roche has announced that its antibody drug conjugate Kadcyla cut the risk of disease recurrence when given after neoadjuvant treatment and surgery to certain breast cancer patients with residual disease.
Kadcyla new deal means NICE positive recommendation in draft guidance europeanpharmaceuticalreview
June 26, 2017
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.